Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)'s stock had its "buy" rating restated by research analysts at Needham & Company LLC in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $22.00 price target on the stock. Needham & Company LLC's price objective points to a potential upside of 85.34% from the stock's current price.

STOK has been the subject of a number of other research reports. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 26th. JPMorgan Chase & Co. raised their price target on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a "neutral" rating in a research note on Tuesday, March 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. Wedbush boosted their target price on Stoke Therapeutics from $13.00 to $17.00 and gave the stock an "outperform" rating in a report on Tuesday, March 26th. Finally, Canaccord Genuity Group upped their target price on Stoke Therapeutics from $18.00 to $21.00 and gave the company a "buy" rating in a report on Tuesday, March 26th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $20.71.

Stoke Therapeutics Stock Down 1.2 %

Shares of Stoke Therapeutics stock traded down $0.15 during trading on Monday, reaching $11.87. The company's stock had a trading volume of 608,897 shares, compared to its average volume of 960,525. The company has a 50-day simple moving average of $10.15 and a two-hundred day simple moving average of $6.62. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40. The company has a market cap of $618.66 million, a price-to-earnings ratio of -5.01 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to analysts' expectations of $3.70 million. As a group, analysts anticipate that Stoke Therapeutics will post -2.28 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the sale, the chief financial officer now owns 20,746 shares in the company, valued at $126,550.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares of the company's stock, valued at approximately $126,550.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Skorpios Trust sold 3,600,000 shares of the stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the sale, the insider now owns 10,843,681 shares of the company's stock, valued at approximately $125,786,699.60. The disclosure for this sale can be found here. Insiders have sold 3,622,741 shares of company stock valued at $41,935,115 in the last quarter. Corporate insiders own 11.30% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds have recently modified their holdings of the stock. Dorsey & Whitney Trust CO LLC purchased a new stake in Stoke Therapeutics during the third quarter worth $43,000. Sherbrooke Park Advisers LLC acquired a new position in Stoke Therapeutics in the 3rd quarter valued at about $48,000. SG Americas Securities LLC purchased a new position in Stoke Therapeutics in the 3rd quarter valued at about $53,000. Corton Capital Inc. acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter worth about $58,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Stoke Therapeutics in the 3rd quarter worth approximately $64,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.